On Nov 07, major Wall Street analysts update their ratings for $CRISPR Therapeutics (CRSP.US)$, with price targets ranging from $30 to $95.
Evercore analyst Liisa Bayko maintains with a hold rating, and maintains the target price at $60.
TD Cowen analyst Tyler Van Buren maintains with a sell rating, and maintains the target price at $30.
Oppenheimer analyst Jay Olson maintains with a buy rating, and maintains the target price at $95.
Stifel analyst Benjamin Burnett maintains with a hold rating, and adjusts the target price from $59 to $53.
Truist Financial analyst Joon Lee maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $CRISPR Therapeutics (CRSP.US)$'s main analysts recently are as follows:
Crispr Therapeutics' third-quarter update underscored the CTX112 ASH abstract in B-cell malignancies, showcasing promising initial efficacy.
The journey for patients using Casgevy isn't brief, yet there are indications of demand starting to emerge. Notably, beyond the first patient infusion, 40 patients have completed at least one cell collection. Analysts remain cautious as they continue to evaluate the time needed to translate patient treatments into revenue and profitability. Looking ahead, the CTX112 ASH2024 abstract showed a 6-month complete response rate of 44% in a mixed lymphoma study. Further insight is anticipated upon full disclosure to better assess the drug's potential in the fields of oncology and autoimmune diseases.
Here are the latest investment ratings and price targets for $CRISPR Therapeutics (CRSP.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月7日，多家华尔街大行更新了$CRISPR Therapeutics (CRSP.US)$的评级，目标价介于30美元至95美元。
Evercore分析师Liisa Bayko维持持有评级，维持目标价60美元。
TD Cowen分析师Tyler Van Buren维持卖出评级，维持目标价30美元。
奥本海默控股分析师Jay Olson维持买入评级，维持目标价95美元。
斯迪富分析师Benjamin Burnett维持持有评级，并将目标价从59美元下调至53美元。
储亿银行分析师Joon Lee维持买入评级。
此外，综合报道，$CRISPR Therapeutics (CRSP.US)$近期主要分析师观点如下：
crispr therapeutics的第三季度更新强调了在B细胞恶性肿瘤中的CTX112 ASH摘要，展示了有希望的初步疗效。
Casgevy患者的旅程并不简短，但有迹象显示需求开始出现。值得注意的是，在首次患者输注之后，已有40名患者完成了至少一次电芯采集。分析师仍然保持谨慎，因为他们继续评估将患者治疗转化为营业收入和盈利所需的时间。展望未来，CTX112 ASH2024摘要显示了在一项混合淋巴瘤研究中的6个月完全缓解率达到44%。随着全面披露，进一步的见解有望更好地评估该药物在肿瘤学和自身免疫疾病领域的潜力。
以下为今日5位分析师对$CRISPR Therapeutics (CRSP.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
